MolecularMD
is a molecular diagnostic laboratory that develops and commercializes oncology precision medicines... Read moreMolecularMD
is a molecular diagnostic laboratory that develops and commercializes oncology precision medicines... Read more
2005
2836 NAICS listing
News
Mar 04, 2019
The Business Journals: Portland
MolecularMD: Portland biotech firm sold to global drug developer
Feb 28, 2019
FierceBiotech
MolecularMD: Icon snaps up molecular DX specialist MolecularMD for undisclosed price
Feb 22, 2019
Contract Pharma
MolecularMD: ICON Acquires MolecularMD
Nov 28, 2018
Genomeweb
MolecularMD: Sysmex, MolecularMD to Collaborate for CDx Development, Commercialization
Nov 13, 2018
4-traders
MolecularMD: First quantitative diagnostic test validated for Treatment-Free Remission for Eligible Patients with Ph+ CML-CP Treated with Tasigna� Cleared by Health Canada
Aug 22, 2018
4-traders
MolecularMD: MolecularMD Launches Validated Tumor Mutation Burden Assay for Immuno-Oncology Clinical Trial Services
Aug 08, 2018
BioPortfolio
MolecularMD: MolecularMD Corp Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13042018 Prices from USD $250
Jun 25, 2018
MolecularMD Youtube Channel
MolecularMD posted a video "2018 CMS Annual Laboratory Public Meeting" on YOUTUBE
Jun 04, 2018
PharmiWeb
MolecularMD: MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®
Dec 23, 2017
PharmiWeb
MolecularMD: MolecularMD obtains FDA Authorization for the MRDx® BCR-ABL Test as a Companion Diagnostic for Treatment-Free Remission in Ph+ CML-CP Patients Treated with Tasigna
MolecularMD Competitors
1
2
3
4
5
6
7
8
9
10